In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on OncoSec Medical (NASDAQ: ONCS), with a price target of $4. The company’s shares closed yesterday at $1.50.
According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -5.8% and a 37.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Currently, the analyst consensus on OncoSec Medical is Moderate Buy and the average price target is $4.50, representing a 200.0% upside.
In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $5 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.95 and a one-year low of $0.88. Currently, OncoSec Medical has an average volume of 1.17M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OncoSec Medical, Inc. engages in the design and commercialize medical products for the treatment of cancer. It involves in the discovery and development of novel immunotherapeutic products to improve treatment options for patients and physicians, which intends to treat oncology indications.
